Transfusion related iron overload in pediatric oncology patients treated at a tertiary care centre and treatment with chelation therapy. Academic Article uri icon

Overview

abstract

  • We conducted a retrospective chart review to determine prevalence of, risk factors for, and liver toxicity associated with Transfusion Related Iron Overload (TRIO) in pediatric cancer patients, and report our experience with Iron Chelation Therapy (ICT). Total number of transfusions was identified as the major risk factor, with a prevalence of 37% in patients receiving ≥10 transfusions. Four patients with TRIO and abnormal liver function tests (LFT) received ICT. Significant decrease in serum ferritin and improvement in LFT were observed, with no serious adverse effects from ICT noted. Guidelines for screening and treatment of TRIO in pediatric oncology are needed.

publication date

  • August 23, 2014

Research

keywords

  • Iron Chelating Agents
  • Iron Overload
  • Leukemia
  • Lymphoma
  • Transfusion Reaction

Identity

Scopus Document Identifier

  • 84911461865

Digital Object Identifier (DOI)

  • 10.1002/pbc.25189

PubMed ID

  • 25154390

Additional Document Info

volume

  • 61

issue

  • 12